VIENNA — At the American Society of Retina Specialists meeting, Susanne Binder, MD, discusses her experience with the Argus II retinal implant from Second Sight. Although the procedure has been completed over 130 times worldwide, this was the first for Austria.
(MedPage Today) — Health news and commentary from around the Web, gathered by the MedPage Today staff.
By: fardal
VIENNA — At the American Society of Retina Specialists meeting, Howard F. Fine, MD, discusses antimicrobial resistance rates in patients who have had repeated courses of antibiotics around the time of a intravitreal injection.
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today announced the first commercial implants of the Argus® II Retinal Prosthesis System (“Argus II”) have been performed in Austria and Turkey, and the first implant in Spain through a distribution agreement with IMEX has been performed. IMEX is the largest
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it continues to fortify the patent protection covering its retinal pigment epithelium (RPE) transplant technology for macular degeneration with the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent No 9,080,150. “The issuance of this 9th U.S. patent in our global RPE portfolio represents yet another example of the